




FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

GSHISHIMA@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3081

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

June 24, 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
June 24, 2002	
Date	Gina N. Shishima

Commissioner for Patents
Washington, DC 20231

Re: *U.S. Patent Application No. 10/057,834 entitled "COMPOSITIONS AND METHODS FOR OPTIMIZING UGT2B7 SUBSTRATE DOSINGS AND FOR PREDICTING UGT2B7 SUBSTRATE TOXICITY" by Mark J. Ratain et al.*
Client Reference: UCHI:846
Our Reference: ARCD:358US

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1, B1, C1-C26).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10200935/GNS.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104

GNS/cmb
Encl.: as noted

25179234.1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Mark J. Ratain *et al.*

Serial No.: 10/057,834

Filed: January 25, 2002

For: COMPOSITIONS AND METHODS FOR
OPTIMIZING UGT2B7 SUBSTRATE
DOSINGS AND FOR PREDICTING
UGT2B7 SUBSTRATE TOXICITY

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: ARCD:358US

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

June 24, 2002

Date

Gina N. Shishima

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10200935/GNS.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: June 24, 2002



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

ARCD:358US

Serial No.

10/057,834

Applicant

Mark J. Ratain *et al.*

Filing Date:

January 25, 2002

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,786,344	7/28/98	Ratain <i>et al.</i>	514	100	4/17/95

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 00/06776	2/10/00	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Barbier <i>et al.</i> , "Accelerated Communication: 3'-azido-3'-deoxythymidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 3B7 (UGT2B7)," <i>Drug Metab Dispos.</i> , 28:497-502, 2000.
	C2	Barker <i>et al.</i> , "Determination of plasma concentrations of epirubicin and its metabolites by high-performance liquid chromatography during a 96-h infusion in cancer chemotherapy," <i>J Chromatogr B Biomed Appl</i> 681:323-329, 1996.
	C3	Bhasker <i>et al.</i> , "Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance," <i>Pharmacogenetics</i> , 10(8):679-685, 2000.
	C4	Carrier <i>et al.</i> , "Isolation and characterization of the human UGT2B7 gene," <i>Biochem and Biophys. Res. Commun.</i> , 272:616-621, 2000.
	C5	Chen <i>et al.</i> , "Fluorescence polarizaton in homogeneous nucleic acid analysis," <i>Genome Res.</i> , 9:492-498, 1999.
	C6	Cheng <i>et al.</i> , "Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7," <i>Toxicological Sciences</i> , 45:52-57, 1998.
	C7	Coffman <i>et al.</i> , "Human UGT2B7 catalyzes morphine glucuronidation," <i>Drug Metab Dispos.</i> , 25:1-4, 1997.
	C8	Coffman <i>et al.</i> , "The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268)," <i>Drug Metab Dispos.</i> , 26:73-77, 1998.

25139727.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

ARCD:358US

10/057,834

U.S. Office of Patents and Publications for Applicant's

Applicant

Mark J. Ratain *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

January 25, 2002

1645

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Dobbs and Twelves, "What is the effect of adjusting epirubicin doses for body surface area?" <i>British Journal of Cancer</i> , 78(5):662-666, 1998.
	C10	Evans and Relling, "Automated high-performance liquid chromatographic assay for the determination of 7-ethoxycoumarin and umbelliferone," <i>J Chromatogr</i> , 578:141-145, 1992.
	C11	GenBank Accession Number NM_001074.
	C12	Gestl <i>et al.</i> , "Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxystosterone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in Situ breast cancers," <i>American Journal of Pathology</i> , 160(4):1467-1479, 2002.
	C13	Hsu <i>et al.</i> , "Universal SNP genotyping assay with fluorescence polarization detection," <i>BioTechniques</i> , 31:560-570, 2001.
	C14	Innocenti <i>et al.</i> , "Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyl transferase 2B7," <i>Drug Metab. Dispos.</i> , 29(5):686-692, 2001.
	C15	Innocenti <i>et al.</i> , "Epirubicin is glucuronidated by UGT2B7," <i>Clinical Pharmacology and Therapeutics</i> , 67(2):100, Abstract PI-44, 2000.
	C16	Ishii <i>et al.</i> , "Octamer transcription factor-1 enhances hepatic nuclear factor-1 α -mediated activation of the human UDP glucuronosyltransferase 2B7 promoter," <i>Molecular Pharmacology</i> 57:940-947, 2000.
	C17	Iyer <i>et al.</i> , "Glucuronidation of TAS-103 by uridine diphosphate glucuronosyltransferase (UGT) isoforms 1a1 and 2: possible implication of TAS-103 toxicity in Gilbert's syndrome," <i>Ann Oncol</i> 9(Supplement 2):61, abstract #230, 1998.
	C18	Jin <i>et al.</i> , "cDNA cloning and expression of two new members of the human glucuronosyltransferase 2B subfamily," <i>Biochem. Biophys. Res. Comm.</i> , 194(1):496-503, 1993.
	C19	Jin <i>et al.</i> , "Complementary deoxyribonucleic acid cloning and expression of human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs," <i>J. Pharm. Experim. Therap.</i> , 264(1):475-479, 1993.
	C20	Mackenzie <i>et al.</i> , "Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance," <i>Clin. Chem. Lab. Med.</i> , 38(9):889-892, 2000.

25139727.1

EXAMINER:


DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)	Atty. Docket No. ARCD:358US	Serial No. 10/057,834
List of Patents and Publications for Applicant's	Applicant Mark J. Ratain <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Filing Date: January 25, 2002	Group: 1645
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1



Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C21	Mackenzie <i>et al.</i> , "The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence," <i>Pharmacogenetics</i> , 7:255-269, 1997.
	C22	Radomska-Pandya <i>et al.</i> , "Human UDP-glucuronosyltransferase 2B7," <i>Curr. Drug. Metab.</i> , 2:283-298, 2001.
	C23	Robert, "Clinical pharmacokinetics of epirubicin," <i>Clin. Pharmacokinet</i> , 26:428-438, 1994
	C24	Strassburg <i>et al.</i> , "Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7," <i>J. Hepat.</i> , 34(6):865-872, 2001
	C25	Toide <i>et al.</i> , "Hepatocyte nuclear factor 1 α is a causal factor responsible for interindividual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in human livers," <i>Drug Metabolism and Disposition</i> , 30(6):613-615, 2002.
	C26	Wade <i>et al.</i> , "Variability in the pharmacokinetics of epirubicin: a population analysis," <i>Cancer Chemother. Pharmacol.</i> , 29:391-395, 1992.

25139727.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.